ENTERO

Entero Healthcare Solutions share price & financials

Price
₹1,174
Market cap
₹6.1k Cr
Sector
Consumer Services
Calls analysed
8
Latest concall · Q1 FY27 · call held 10 Aug 2026

Entero Healthcare Solutions Limited Q1 FY27

Consolidated Revenue ₹1,940 cr +38%EBITDA Margin 5% Profit After Tax ₹52 cr +72%ROCE 21.1%

What went well

  • Consolidated revenue grew 38.2% year-on-year to INR1,940 crores, with like-for-like growth at 40% year-on-year.
  • EBITDA margin expanded 143 basis points to 5% for the quarter, achieving the full year FY27 guidance in Q1 itself.
  • Profit after tax (PAT) for the quarter was INR52 crores, up 72% year-on-year, with PAT attributable to owners at INR38 crores, up 37% year-on-year.

What to watch

  • Reported growth was impacted by around 2.5% due to the conscious exit from certain low-margin businesses.
  • Non-controlling interest stood at INR14 crores for the quarter, representing approximately 27% of profit before minority interest, though management clarified this is a function of business outperformance.
Read the full call →

What Entero Healthcare Solutions Limited does

Entero Healthcare Solutions is a healthcare products supply-chain and distribution company operating in India's pharmaceutical and, more recently, MedTech (IVD, cardiology, orthopedics) markets. It sources from pharmaceutical and healthcare product manufacturers and moves goods through central warehousing and pan-India redistribution to retail pharmacies and hospitals, earning distribution margins on the goods it handles. Beyond product fulfilment, it also offers manufacturers demand-generation services such as deploying medical representatives and managing marketing/channel strategy. The company operates as a single reportable wholesale-distribution segment and has grown its footprint substantially through an active acquisition programme alongside organic expansion.

Market position
Among the top three healthcare products distributors in India by revenue
Warehouses
136
Districts covered
523
Cities with presence
~50
States & Union Territories covered
20+
Retail pharmacy customers
1,05,300+
Founded 2018Headquarters Faridabad, Haryana, IndiaEmployees 4,111 (2025-03-31) Company website

Guidance record · Q1 FY27

what the last two calls moved 26 tracked 9 delivered 3 missed 14 open
  • Long-term Return on Equity (ROE) delivered said Q4 FY24 Promised: 20% plus in 2-3 years Q1 FY27: Q1 FY27 ROE was reported at 20.4%, meeting the original long-term target of '20% plus' well ahead of the previously diluted timeline.
  • FY25 Revenue Growth missed said Q4 FY24 Promised: 35% to 40% revenue growth in FY '25 Q1 FY27: This promise pertains to a past financial year (FY25) and was not addressed.
  • Long-term EBITDA Margin on track said Q4 FY25 Promised: close to 5% beyond FY26 Q1 FY27: Achieved 5.0% EBITDA margin in Q1 FY27, hitting the long-term target in the first quarter beyond FY26. This demonstrates strong progress towards sustaining this level.

All 26 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 38.2%, net profit up 73.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,301 1,359 1,339 1,404 1,571 +21%1,707 +26%1,910 +43%1,940 +38%
EBITDA42 50 49 50 62 +48%68 +36%86 +76%97 +94%
Net profit26 29 31 30 37 +42%34 +17%45 +45%52 +73%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +51.8% 1Y

₹1.0k₹1.2k₹1.4k₹1.6k₹1.8kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 13 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 2 Jun 2026Q1 FY27 — 10 Aug 2026

1Y: ₹1,195.7 on 10 Sept 2025 → ₹1,815.4. High ₹1,898.4 (7 Sept 2026), low ₹949.2 (29 Dec 2025).

How the price took the results

close before → close after

Q1 FY27
+5.8%
10 Aug
Q4 FY26
+1.0%
2 Jun
Q3 FY26
−0.7%
13 Feb
Q2 FY26
+1.1%
13 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 29.6% a year over 2 years, FY24 to FY26. Operating margin widened to 4.0%.

Year endingFY24FY25FY26
Revenue₹3.9k Cr₹5.1k Cr₹6.6k Cr
Operating profit₹113 Cr₹171 Cr₹266 Cr
Operating margin2.9%3.4%4.0%
Interest₹65 Cr₹41 Cr₹54 Cr
Depreciation₹25 Cr₹30 Cr₹44 Cr
Net profit₹39 Cr₹107 Cr₹146 Cr
Net margin1.0%2.1%2.2%
Cash from operations₹-37 Cr₹-77 Cr₹96 Cr
Free cash flow₹-41 Cr₹-87 Cr₹29 Cr
ROCE7.0%9.0%10.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹0 Cr₹4 Cr₹4 Cr₹43 Cr₹44 Cr₹44 Cr
Reserves₹-32 Cr₹-62 Cr₹-73 Cr₹1.6k Cr₹1.7k Cr₹1.6k Cr
Borrowings₹720 Cr₹974 Cr₹1.1k Cr₹338 Cr₹443 Cr₹677 Cr
Other liabilities₹147 Cr₹210 Cr₹275 Cr₹369 Cr₹642 Cr₹1.2k Cr
Total liabilities₹836 Cr₹1.1k Cr₹1.3k Cr₹2.3k Cr₹2.9k Cr₹3.6k Cr
Fixed assets₹189 Cr₹262 Cr₹268 Cr₹289 Cr₹627 Cr₹958 Cr
Capital work in progress₹2 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr₹2 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹67 Cr₹130 Cr
Other assets₹645 Cr₹863 Cr₹1.0k Cr₹2.1k Cr₹2.2k Cr₹2.5k Cr
Total assets₹836 Cr₹1.1k Cr₹1.3k Cr₹2.3k Cr₹2.9k Cr₹3.6k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, FIIs trimmed −12.85 pp while the public added +7.58 pp. The shareholder count grew 19% to 39,709.

Promoters
52.4%
FIIs
4.4%
DIIs
15.5%
Public
27.8%

Since Jun 2025

  • FIIs −12.85 pp
  • Public +7.58 pp
  • DIIs +5.29 pp

How it drifted, 10 quarters

Over this window FIIs fell from 23.3% to 4.4% — −18.9 pp.

Mar '24Mar '25Jun '26

Ownership split by quarter, oldest first. Mar '24: Promoters 52.4%, FIIs 23.3%, DIIs 2.3%, Public 22.0%.Jun '24: Promoters 52.4%, FIIs 23.3%, DIIs 2.1%, Public 22.2%.Sep '24: Promoters 52.4%, FIIs 23.8%, DIIs 7.7%, Public 16.0%.Dec '24: Promoters 52.4%, FIIs 22.2%, DIIs 8.8%, Public 16.6%.Mar '25: Promoters 52.4%, FIIs 19.9%, DIIs 9.6%, Public 18.0%.Jun '25: Promoters 52.4%, FIIs 17.2%, DIIs 10.2%, Public 20.2%.Sep '25: Promoters 52.4%, FIIs 14.7%, DIIs 9.6%, Public 23.3%.Dec '25: Promoters 52.4%, FIIs 5.1%, DIIs 16.4%, Public 26.0%.Mar '26: Promoters 52.4%, FIIs 4.0%, DIIs 16.6%, Public 26.9%.Jun '26: Promoters 52.4%, FIIs 4.4%, DIIs 15.5%, Public 27.8%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 3 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Entero Healthcare Solutions Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Orbimed Asia III Mauritius Limited 38.00%unchanged
Surbhi Singh(Prasid Uno Family Trust) 10.45%unchanged
Prabhat Agrawal 9.26%unchanged
Prem Sethi 5.15%unchanged
Invesco India Aggressive Hybrid Fund Mutual fund4.31%unchanged
ICICI Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund Mutual fund2.16%newly disclosed
Bank Of India Flexi Cap Fund Mutual fund2.12%newly disclosed
Cif Iii Scheme I AIF1.95%unchanged
Arti Mittal 0.00%unchanged
OrbiMed Asia Partners III, L.P. 0.00%unchanged
Uquifa India Limited 0.00%unchanged
Soneas Chemicals Hungary 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Attractive

To justify its price of ₹1815, this stock must grow earnings at 29% every year for 7 years. Our analysis caps realistic growth at ~93%. At that growth it is worth ₹26225 — upside of 1345%.

Growth the price implies
29.4% a year
for 7 years, fading to 4%
It has actually compounded at
93.5% a year
net profit, FY24–FY26
The gap
-0.6 pp
1345% downside if it only repeats history
Price today ₹1,815.4 Value at the reference growth ₹26,224.79

Change the assumptions yourself →

All earnings calls (8)

Read the Q1 FY27 call →

Learn to analyse Entero Healthcare Solutions Limited

Guides on how to read this kind of business and the numbers that matter.